Claims for Patent: 10,058,615

Summary for Patent: 10,058,615

Title:	Semifluorinated alkane compositions
Abstract:	The invention provides novel compositions comprising semifluorinated alkanes and at least one compound sensitive or prone to oxidation. The compositions can be used as medicines that are topically administered to an eye or ophthalmic tissue. The invention further provides kits comprising such compositions.
Inventor(s):	Günther Bernhard, Scherer Dieter, Pettigrew Anthony, Theisinger Bastian, Theisinger Sonja
Assignee:	NOVALIQ GMBH
Application Number:	US15428031
Patent Claims:	1. A method of treating a disease or condition of a patient in need of such treatment , comprising administering an effective amount of a stable liquid composition , wherein the composition consists of a semifluorinated alkane of the formula F(CF)(CH)H , wherein n is an integer from 3 to 8 and m is an integer from 3 to 10 , and optionally one or more excipients , wherein the composition is topically administered to an eye or ophthalmic tissue of the patient , and wherein the disease or condition is an inflammatory condition of the ophthalmic tissue or keratoconjunctivitis sicca (dry eye) and symptoms or conditions associated therewith.2. The method according to claim 1 , wherein the one or more excipient is selected from the group consisting of a lipid claim 1 , oil claim 1 , lubricant claim 1 , lipophilic vitamin claim 1 , viscosity agent claim 1 , antioxidant claim 1 , surfactant and mixtures of two or more thereof.3. The method according to claim 1 , wherein the semifluorinated alkane is a liquid selected from the group consisting of F(CF)(CH)H claim 1 , F(CF)(CH)H claim 1 , F(CF)(CH)H claim 1 , F(CF)(CH)H claim 1 , F(CF)(CH)H claim 1 , F(CF)(CH)H claim 1 , and F(CF)(CH)H.4. The method according to claim 1 , wherein the symptom associated with keratoconjunctivitis sicca is selected from one or more of dry claim 1 , scratchy claim 1 , gritty claim 1 , or sandy feeling in the eye; foreign body sensation; pain or soreness; stinging or burning; itching; increased blinking; eye fatigue; photophobia; blurry vision; redness; mucus discharge; contact lens intolerance; and excessive reflex tearing.5. The method according to claim 1 , wherein the method comprises administering the composition to the cornea or conjunctiva claim 1 , or the upper or lower eye lid margins claim 1 , meibomian gland ducts claim 1 , or eyelashes.6. The method according to claim 1 , wherein the composition is free of water and free of a preservative.7. The method according to claim 1 , wherein the condition associated with keratoconjunctivitis sicca is selected from the group consisting of aqueous-deficient dry eye disease claim 1 , evaporative dry eye disease claim 1 , Sjögren syndrome claim 1 , lacrimal gland insufficiency claim 1 , meibomian gland disease and meibomian gland dysfunction.8. The method according to claim 7 , wherein the condition associated with keratoconjunctivitis sicca is meibomian gland dysfunction based on abnormalities of the meibomian glands characterized by gland duct obstructions and/or changes to the secretions of the glands.9. The method according to claim 7 , wherein the condition associated with keratoconjunctivitis sicca is meibomian gland dysfunction characterized by a symptom selected from one or more of itchiness claim 7 , redness claim 7 , swelling claim 7 , pain or soreness claim 7 , discharge accumulation or crusting at the lid margins.